Direct Costs of Care for Adults with Soft Tissue Sarcomas: A Population-Based Study
Authors:
- Massimo RuggeMRMassimo Rugge
- Alessandra BujaABAlessandra Buja
- Saveria TropeaSTSaveria Tropea
- Giovanni GirardiGGGiovanni Girardi
- Luigi Cosenza FranzeseLFLuigi Cosenza Franzese
- Claudia CozzolinoCCClaudia Cozzolino
- Manuel ZorziMZManuel Zorzi
- Antonella VecchiatoAVAntonella Vecchiato
- Paolo Del FiorePFPaolo Del Fiore
- Antonella BrunelloAntonella Brunello
- Alessandra Rosalba BrazzaleABAlessandra Rosalba Brazzale
- Vincenzo BaldoVincenzo Baldo
Open Access
Abstract
The clinical treatment of soft tissue sarcoma (STS) has evolved substantially over the last decade. This population-based cohort study based on real-world data included all incidental STS recorded by the Veneto Cancer Registry in 2017. Data on hospital admissions, emergency department and outpatient visits, drug prescriptions, and use of medical devices within two years from STS diagnosis were obtained from administrative databases. The average per-patient real-world costs over this two-year period, in total and by single expenditure item, were calculated and stratified by stage of disease at diagnosis, tumor histology and tumor site. The mean total cost per patient amounted to EUR 16,793. A higher TNM stage at diagnosis was associated with higher healthcare costs, as follows: compared with stage I, the average total cost per patient was 1.32, 2.18 and 3.36 times greater for stages II, III and IV, respectively. Hospital stays generated the greatest costs (averaging EUR 7950 per patient), followed by outpatient visits (mean EUR 3947 per patient) and drug prescriptions (mean EUR 3664 per patient). Given the paucity of population-based studies, the present results can serve as a reference for further cost-effectiveness analyses on care strategies for patients with STS.Keywords
Funding Information
- Ricerca Corrente 2022
This publication has 19 references indexed in Scilit:
- The 2020 WHO Classification of Soft Tissue Tumours: news and perspectivesPathologica, 2020
- Soft‐tissue sarcoma in adults: An update on the current state of histiotype‐specific management in an era of personalized medicineCA: A Cancer Journal for Clinicians, 2020
- The cost of cancer in Europe 2018European Journal of Cancer, 2020
- Health Care Resource Utilization and Costs among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and FranceSarcoma, 2018
- The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer stagingCA: A Cancer Journal for Clinicians, 2017
- Cost of treatment in patients with metastatic soft tissue sarcoma who respond favourably to chemotherpy. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) studyEuropean Journal of Cancer Care, 2015
- Análisis de los costes de diagnóstico y tratamiento de los sarcomas de partes blandas en centros de referenciaRevista Española de Cirugía Ortopédica y Traumatología, 2012
- Incidence of soft tissue sarcoma and beyondCancer, 2012
- Clinicians' adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regionsBMC Health Services Research, 2012
- Increasing incidence rates of soft tissue sarcomas? A population-based epidemiologic study and literature reviewAnnals of Oncology, 2009